StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Shandong Weigao Blood Purification Products Co. Ltd. logo

Shandong Weigao Blood Purification Products Co. Ltd.

603014 · XSHG · Medical Devices · China

Market Capitalization16.57B CNY
Trailing P/E32.78 CNY
52-Week Change-5.67 CNY
Forward Annual Dividend Yield0.40%

Shandong Weigao Blood Purification Products Co. Ltd. is a leading medical technology company specializing in blood purification solutions. Established in 2004 and headquartered in Weihai, Shandong Province, the company is recognized as a domestic industry leader with independent core technologies in blood purification. Its primary focus is on research, development, production, and sales of a comprehensive range of products for hemodialysis and peritoneal dialysis, including dialyzers, dialysis machines, bloodlines, and peritoneal dialysis solutions. Through continuous investment in R&D and strategic collaborations with international medical enterprises like Terumo and NIKKISO, Shandong Weigao has built a vertically integrated supply chain that addresses all aspects of blood purification treatment. The company plays a pivotal role in supporting hospitals and medical practitioners in the management of kidney disease, contributing significantly to the healthcare sector and improving the quality of life for kidney patients both in China and internationally. Its commitment to quality and innovation has established it as a key player in the medical devices and health technology market.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in Shandong Weigao Blood Purification Products Co. Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
16.57BCNY
NormalMar 19, 2026
Trailing P/E
32.78CNY
NormalMar 19, 2026
Revenue (TTM)
3.70BCNY
NormalMar 19, 2026
Profit Margin
12.84%
NormalMar 19, 2026
52-Week Change
-5.67CNY
ExtremeMar 19, 2026
Forward Annual Dividend Yield
0.40%
NormalMar 19, 2026
Forward Yield
0.40%
Annual Rate
CNY 0.16
Paid unknown
Payout Ratio
0.0%
Sustainable
Loading dividend history...

Track Record

Frequency
Unknown
Payback Period
234.1 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Oct 24, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
16.57BCNY
NormalMar 19, 2026
Enterprise Value
13.96BCNY
NormalMar 19, 2026
Trailing P/E
32.78CNY
NormalMar 19, 2026
Forward P/E
33.90CNY
NormalMar 19, 2026
PEG Ratio
33.90CNY
ExtremeMar 19, 2026
Price to Sales (TTM)
4.48CNY
NormalMar 19, 2026
Price to Book (MRQ)
2.37CNY
NormalMar 19, 2026
Enterprise to Revenue
3.78CNY
NormalMar 19, 2026
Enterprise to EBITDA
18.26CNY
NormalMar 19, 2026
Profitability & Growth19
Gross Margin
41.29%
NormalMar 19, 2026
Profit Margin
12.84%
NormalMar 19, 2026
Operating Margin
14.65%
NormalMar 19, 2026
Return on Assets (TTM)
0.0643CNY
NormalMar 19, 2026
Return on Equity (TTM)
0.0803CNY
NormalMar 19, 2026
Revenue (TTM)
3.70BCNY
NormalMar 19, 2026
Revenue per Share (TTM)
9.42CNY
NormalMar 19, 2026
Quarterly Revenue Growth
-0.0460CNY
NormalMar 19, 2026
Gross Profit (TTM)
1.51BCNY
NormalMar 19, 2026
EBITDA
545.85MCNY
ExtremeMar 19, 2026
Net Income (TTM)
474.39MCNY
NormalMar 19, 2026
Quarterly Earnings Growth (YoY)
0.0410CNY
NormalMar 19, 2026
Operating Cash Flow (TTM)
760.49MCNY
NormalMar 19, 2026
Levered Free Cash Flow (TTM)
449.37MCNY
NormalMar 19, 2026
Forward Annual Dividend Rate
0.1600CNY
NormalMar 19, 2026
Forward Annual Dividend Yield
0.40%
NormalMar 19, 2026
Trailing Annual Dividend Rate
0.1580CNY
NormalMar 19, 2026
Trailing Annual Dividend Yield
0.40%
NormalMar 19, 2026
Payout Ratio
0.00CNY
NormalMar 19, 2026
Financial Strength10
Shares Outstanding
411.39MShares
NormalMar 19, 2026
Float Shares
65.16MCNY
NormalMar 19, 2026
% Held by Insiders
0.7960CNY
NormalMar 19, 2026
% Held by Institutions
0.0370CNY
NormalMar 19, 2026
Total Cash (MRQ)
2.62BCNY
NormalMar 19, 2026
Total Cash per Share (MRQ)
6.26CNY
NormalMar 19, 2026
Total Debt (MRQ)
5.13MCNY
NormalMar 19, 2026
Total Debt to Equity (MRQ)
0.0740CNY
NormalMar 19, 2026
Current Ratio (MRQ)
3.20CNY
AboveNormalMar 19, 2026
Book Value per Share (MRQ)
16.71CNY
NormalMar 19, 2026
Market & Technical8
52-Week Low
35.00CNY
NormalMar 19, 2026
52-Week High
49.99CNY
NormalMar 19, 2026
52-Week Change
-5.67CNY
ExtremeMar 19, 2026
50-Day MA
40.46CNY
NormalMar 19, 2026
200-Day MA
39.77CNY
NormalMar 19, 2026
Avg 10-Day Volume
875.06KCNY
NormalMar 19, 2026
Avg 30-Day Volume
1.07MCNY
NormalMar 19, 2026
Diluted EPS (TTM)
1.21CNY
NormalMar 19, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.